ArticleFrontiers in oncology2025

Differences in treatment response and survival between HER2(2+)/FISH-positive and HER2(3+) breast cancer patients after dual-target neoadjuvant therapy: a matched case-control study.

Sicheng Zhou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.